The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Kontsevaia A.V.

Gosudarstvennyĭ nauchno-issledovatel'skiĭ tsentr profilakticheskoĭ meditsiny, Moskva

Drapkina O.M.

Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova, Klinika propedevtiki vnutrennikh bolezneĭ, gastroénterologii i gepatologii

Economics of the prevention of chronic non-communicable diseases

Authors:

Kontsevaia A.V., Drapkina O.M.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2018;21(2): 4‑10

Read: 3605 times


To cite this article:

Kontsevaia AV, Drapkina OM. Economics of the prevention of chronic non-communicable diseases. Russian Journal of Preventive Medicine. 2018;21(2):4‑10. (In Russ.)
https://doi.org/10.17116/profmed20182124-10

Recommended articles:
Problems and prospects of medi­cal care for obese patients. Russian Journal of Preventive Medi­cine. 2024;(11):21-26
Features of como­rbidity pathology in young people. Russian Journal of Preventive Medi­cine. 2024;(11):63-69
Study of opinions of medi­cal students on medi­cal prevention issues. Russian Journal of Preventive Medi­cine. 2024;(12):69-74
Risk factors asso­ciated with myopic macu­lopathy in acquired myopia. Russian Annals of Ophthalmology. 2024;(5):35-45
Comparison of models for prediction of spontaneous preterm birth. Medi­cal Technologies. Asse­ssment and Choice. 2024;(4):10-19

References:

  1. Action plan for the prevention and control of noncommunicable diseases in the WHO European Region. Copenhagen: WHO Regional Office for Europe; 2016.
  2. Reeves A, Basu S, McKee M, Meissner C, Stuckler D. Does investment in the health sector promote or inhibit economic growth? Global Health. 2013;9:43.
  3. de la Maisonneuve C, Martins JO. The future of health and long-term care spending. OECD J Econ Stud. 2015;2014:61-96.
  4. Schuring M, Robroek S, Otten F, Arts CH, Burdorf A. The effect of ill health and socioeconomic status on labor force exit and re-employment: a prospective study with ten years follow-up in The Netherlands. Scand J Work Environ Health. 2013;39:134-143. https://doi.org/10.5271/sjweh.3321
  5. Pearson-Stuttard J, Hooton W, Critchley J, et al. Cost-effectiveness analysis of eliminating industrial and all trans fats in England and Wales: modelling study. J Public Health (Oxf). 2017 Sep 1;39(3):574-582. https://doi.org/10.1093/pubmed/fdw095
  6. McDaid D, Sassi F, Merkur S. Promoting health, preventing disease: the economic case. European Observatory on Health Systems and Policies (Copenhagen). 2015.
  7. Buck D. Local action on health inequalities: understanding the economics of investments in the social determinants of health. Public Health England (London). 2014 (Health Equity Briefing).
  8. Stuckler D, Reeves A, McKee M. Social and economic multipliers: what they are and why they are important for health policy in Europe. Scandinavian Journal of Public Health. 2017;45(Suppl 18):17-21.
  9. Beeler AGR, Kakoli R, Lang JE. Absenteeism and employer costs associated with chronic diseases and health risk factors in the US Workforce. Prev Chronic Dis. 2016;13:E141.
  10. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses second panel on cost-effectiveness in health and medicine. JAMA. 2016; 316(10):1093-1103. https://doi.org/10.1001/jama.2016.12195
  11. Mendis S, Chestnov O. Policy reform to realize the commitments of the political declaration on noncommunicable diseases. Br Med Bull. 2013; 105(1):7-27.
  12. Leal J, Luengo-Fernandez R, Gray A, Petersen S, Rayner M. Economic burden of cardiovascular disease in the enlarged European Union. Eur Heart. 2006;27:1610-1619.
  13. The economic cost of cardiovascular disease from 2014—2020 in six European economies. Cerb. 2014. https://cebr.com/wp-content/uploads/2015/08/Short-Report-18.08.14.pdf
  14. Mozaffarian D, Benjamin E, Go A, et al on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics — 2016 update: a report from the American Heart Association. Circulation. 2016;133:000-000.
  15. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013 Nov;14(12):1165-1174. https://doi.org/10.1016/S1470-2045(13)70442-X
  16. de Oliveira C, Weir S, Rangrej J, et al. The economic burden of cancer care in Canada: a population-based cost study. CMAJO. 2018;6:1:E1-E10.
  17. Oganov RG, Kontsevaya AV, Kallinina AM. Economic damage from cardiovascular diseases in the Russian Federation. Cardiovascular therapy and prevention. 2011;10(4):4-9. (In Russ.)
  18. Dedov II, Kontsevaya AV, Shestakova MV, et al. The economic costs of type 2 diabetes mellitus and its major cardiovascular complications in Russian Federation. Diabetes. 2016;19(6):518-527. (In Russ.)
  19. Eriksen M, MacKay J, Schluger N, et al. The Tobacco Atlas. 5th. edition. American Cancer Society (Atlanta, GA). 2015;46.
  20. Anderson P, Moller L, Galea G. Alcohol in the European Union: consumption, harm and policy approaches. WHO Regional Office for Europe (Copenhagen). 2012. http://www.euro.who.int/en/health-topics/disease-prevention/alcohol-use/publications/2012/alcohol-in-the-european-union.-consumption,-harmand policy-approaches, accessed 5 September 2014
  21. Sassi F, Belloni A. Fiscal incentives, behavior change and health promotion: what place in the health-in-all-policies toolkit? Health Promot Int. 2014;29:suppl 1:i103-i112.
  22. Kontsevaya AV, Kalinina AM. The cost of the health care system of Russia associated with Smoking. RPC. 2011;7(3):306-312. (In Russ.)
  23. Krysanova VS, Zhuravleva MV, Dralova OV, et al. The problem of obesity and overweight in Russian Federation and its pharmacological assessment. Almanac of clinical medicine. 2015;1:36-41. (In Russ.)
  24. Yates BT, Marra M. Social return on investment (SROI): problems, solutions and is SROI a good investment? Eval Program Plann. 2016;64:136-144.
  25. Owen L, Morgan A, Fischer A, Ellis S, Hoy A, Kelly MP. The cost-effectiveness of public health interventions. J Public Health. 2012;34(1):37-45.
  26. Best Buys’ and other recommended interventions for the prevention and control of noncommunicable diseases updated (2017) appendix 3 of the Global action for the prevention and control of noncommunicable diseases 2013—2020.
  27. Gaziano TA, Galea G, Reddy KS. Scaling up interventions for chronic disease prevention: the evidence. Lancet. 2007;370(9603):1939-1946.
  28. Magnus A, Haby M, Carter R. The cost-effectiveness of removing television advertising of high-fat and/or high-sugar food and beverages to Australian children. Int J Obes (Lond). 2009;33:1094-1102.
  29. Rubinstein A, Colantonio L, Bardach A, Caporale J, Marti SG, Kopitowski K, et al. Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost–effectiveness analysis of preventative interventions to reduce this burden in Argentina. BMC Public Health. 2010;627.
  30. Kontsevaya AV, Kalinina AM, Boytsov SA, Ipatov PV. Socio-economic efficiency of clinical examination in 2013 in Russian Federation. Cardiovascular therapy and prevention. 2014;13(3):4-10. (In Russ.)
  31. Pyrikova NV, Osipova IV, Kontsevaya AV, et al. Clinical and economic efficiency of organizational model of primary prevention of cardiovascular diseases in railway transport workers. Russian journal of cardiology. 2014;6(110):12-18. (In Russ.)

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.